BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nishida T, Kataoka H. Glypican 3-Targeted Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2019;11. [PMID: 31510063 DOI: 10.3390/cancers11091339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 38] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Xu W, Ye C, Qing X, Liu S, Lv X, Wang W, Dong X, Zhang Y. Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy. Mater Today Bio 2022;16:100358. [PMID: 35880099 DOI: 10.1016/j.mtbio.2022.100358] [Reference Citation Analysis]
2 Wang H, Wang X, Ye X, Ju Y, Cao N, Wang S, Cai J. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma. BMC Cancer 2022;22:814. [PMID: 35879685 DOI: 10.1186/s12885-022-09861-1] [Reference Citation Analysis]
3 Sibuh BZ, Gahtori R, Al-Dayan N, Pant K, Far BF, Malik AA, Gupta AK, Sadhu S, Dohare S, Gupta PK. Emerging trends in immunotoxin targeting cancer stem cells. Toxicol In Vitro 2022;83:105417. [PMID: 35718257 DOI: 10.1016/j.tiv.2022.105417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chong H, Gong Y, Zhang Y, Dai Y, Sheng R, Zeng M. Radiomics on Gadoxetate Disodium-enhanced MRI: Non-invasively Identifying Glypican 3-Positive Hepatocellular Carcinoma and Postoperative Recurrence. Acad Radiol 2022:S1076-6332(22)00254-9. [PMID: 35562264 DOI: 10.1016/j.acra.2022.04.006] [Reference Citation Analysis]
5 Lv X, Chen J, He J, Hou L, Ren Y, Shen X, Wang Y, Ji T, Cai X. Gasdermin D-mediated pyroptosis suppresses liver regeneration after 70% partial hepatectomy. Hepatol Commun 2022. [PMID: 35509206 DOI: 10.1002/hep4.1973] [Reference Citation Analysis]
6 Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333 [DOI: 10.12998/wjcc.v10.i11.3321] [Reference Citation Analysis]
7 Dituri F, Gigante G, Scialpi R, Mancarella S, Fabregat I, Giannelli G. Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma. Cancers 2022;14:1902. [DOI: 10.3390/cancers14081902] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mu W, Chu Q, Yang H, Guan L, Fu S, Gao T, Sang X, Zhang Z, Liang S, Liu Y, Zhang N. Multipoint Costriking Nanodevice Eliminates Primary Tumor Cells and Associated-Circulating Tumor Cells for Enhancing Metastasis Inhibition and Therapeutic Effect on HCC. Adv Sci (Weinh) 2022;9:2101472. [PMID: 35356152 DOI: 10.1002/advs.202101472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Shao L, Yu X, Han Q, Zhang X, Lu N, Zhang C. Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma. OncoImmunology 2022;11:2010894. [DOI: 10.1080/2162402x.2021.2010894] [Reference Citation Analysis]
10 Fasano R, Shadbad MA, Brunetti O, Argentiero A, Calabrese A, Nardulli P, Calbi R, Baradaran B, Silvestris N. Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life (Basel) 2021;11:1355. [PMID: 34947886 DOI: 10.3390/life11121355] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Filippi L, Braat AJ. Theragnostics in primary and secondary liver tumors: the need for a personalized approach. Q J Nucl Med Mol Imaging 2021;65:353-70. [PMID: 34881847 DOI: 10.23736/S1824-4785.21.03407-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Savier E, Simon-Gracia L, Charlotte F, Tuffery P, Teesalu T, Scatton O, Rebollo A. Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma. Pharmaceutics 2021;13:1631. [PMID: 34683924 DOI: 10.3390/pharmaceutics13101631] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
13 Wang H, Chen X, Calvisi DF. Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opin Ther Targets 2021;25:645-58. [PMID: 34477018 DOI: 10.1080/14728222.2021.1976142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhuo J, Lu D, Wang J, Lian Z, Zhang J, Li H, Cen B, Wei X, Wei Q, Xie H, Xu X. Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts. Chin J Cancer Res 2021;33:470-9. [PMID: 34584372 DOI: 10.21147/j.issn.1000-9604.2021.04.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Han J, Thurnherr T, Chung AYF, Goh BKP, Chow PKH, Chan CY, Cheow PC, Lee SY, Lim TKH, Chong SS, Ooi LLPJ, Lee CG. Clinicopathological-Associated Regulatory Network of Deregulated circRNAs in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2772. [PMID: 34199580 DOI: 10.3390/cancers13112772] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Wang JY, Wang XK, Zhu GZ, Zhou X, Yao J, Ma XP, Wang B, Peng T. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma. BMC Cancer 2021;21:462. [PMID: 33902495 DOI: 10.1186/s12885-021-08104-z] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
17 Zhao J, Gao S, Sun W, Grimm R, Fu C, Han J, Sheng R, Zeng M. Magnetic resonance imaging and diffusion-weighted imaging-based histogram analyses in predicting glypican 3-positive hepatocellular carcinoma. Eur J Radiol 2021;139:109732. [PMID: 33905978 DOI: 10.1016/j.ejrad.2021.109732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Irshad K, Malik N, Arora M, Gupta Y, Sinha S, Chosdol K. The quest for ligands and binding partners of atypical cadherin FAT1. Transl Oncol 2021;14:101097. [PMID: 33878524 DOI: 10.1016/j.tranon.2021.101097] [Reference Citation Analysis]
19 Guan MC, Wang MD, Liu SY, Ouyang W, Liang L, Pawlik TM, Xu QR, Huang DS, Shen F, Zhu H, Yang T. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside. World J Gastrointest Oncol 2021; 13(4): 197-215 [PMID: 33889272 DOI: 10.4251/wjgo.v13.i4.197] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
20 Sun L, Gao F, Gao Z, Ao L, Li N, Ma S, Jia M, Li N, Lu P, Sun B, Ho M, Jia S, Ding T, Gao W. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. J Immunother Cancer 2021;9:e001875. [PMID: 33833049 DOI: 10.1136/jitc-2020-001875] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
21 Yu L, Huang N, Sun H, Yang X, Fu Y, Lang Q, Wang J, Ge L. Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma. J Immunother 2021;44:106-13. [PMID: 33239522 DOI: 10.1097/CJI.0000000000000349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Labadie KP, Ludwig AD, Lehnert AL, Hamlin DK, Kenoyer AL, Sullivan KM, Daniel SK, Mihailovic TN, Sham JG, Orozco JJ, Yeung RS, Chen DL, Wilbur DS, Miyaoka RS, Park JO. Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma. Sci Rep 2021;11:3731. [PMID: 33580090 DOI: 10.1038/s41598-021-82172-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Shi X, Chen M, Feng H, Zhou Z, Wu R, Li W, Liang J, Chen J, Li G. Glypican-3 electrochemical aptasensor based on reduced graphene oxide‐chitosan‐ferrocene deposition of platinum–palladium bimetallic nanoparticles. J Appl Electrochem 2021;51:781-94. [DOI: 10.1007/s10800-021-01534-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
24 Dong W, Yan K, Yu H, Huo L, Xian Z, Zhao Y, Li J, Zhang Y, Cao Z, Fu Y, Cong W, Dong H. Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Front Oncol 2020;10:605057. [PMID: 33643907 DOI: 10.3389/fonc.2020.605057] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 Ikeda M, Okusaka T, Ohno I, Mitsunaga S, Kondo S, Ueno H, Morizane C, Gemmoto K, Suna H, Ushida Y, Furuse J. Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma. Immunotherapy 2021;13:371-85. [PMID: 33525928 DOI: 10.2217/imt-2020-0278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
26 Nomura K, Kitanaka A, Iwama H, Tani J, Nomura T, Nakahara M, Ohura K, Tadokoro T, Fujita K, Mimura S, Yoneyama H, Kobara H, Morishita A, Okano K, Suzuki Y, Tsutsi K, Himoto T, Masaki T. Association between microRNA-527 and glypican-3 in hepatocellular carcinoma. Oncol Lett 2021;21:229. [PMID: 33613718 DOI: 10.3892/ol.2021.12490] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Xiong X, Xi J, Liu Q, Wang C, Jiang Z, Yue SY, Shi L, Rong Y. Co-expression of IL-7 and PH20 promote anti-GPC3 CAR-T tumour suppressor activity in vivo and in vitro. Liver Int 2021;41:1033-43. [PMID: 33347692 DOI: 10.1111/liv.14771] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
28 Houvast RD, Vankemmelbeke M, Durrant LG, Wuhrer M, Baart VM, Kuppen PJK, de Geus-Oei LF, Vahrmeijer AL, Sier CFM. Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging. Cancers (Basel) 2020;12:E3870. [PMID: 33371487 DOI: 10.3390/cancers12123870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
29 Li G, Feng H, Shi X, Chen M, Liang J, Zhou Z. Highly sensitive electrochemical aptasensor for Glypican-3 based on reduced graphene oxide-hemin nanocomposites modified on screen-printed electrode surface. Bioelectrochemistry 2021;138:107696. [PMID: 33254049 DOI: 10.1016/j.bioelechem.2020.107696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
30 Cui TM, Liu Y, Wang JB, Liu LX. Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:11725-40. [PMID: 33235462 DOI: 10.2147/OTT.S279858] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
31 Sherif IO, Al-Mutabagani LA, Sabry D, Elsherbiny NM. Antineoplastic Activity of Chrysin against Human Hepatocellular Carcinoma: New Insight on GPC3/SULF2 Axis and lncRNA-AF085935 Expression. Int J Mol Sci 2020;21:E7642. [PMID: 33076548 DOI: 10.3390/ijms21207642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
32 Zhang L, Ding J, Li HY, Wang ZH, Wu J. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim Biophys Acta Rev Cancer 2020;1874:188441. [PMID: 33007432 DOI: 10.1016/j.bbcan.2020.188441] [Cited by in Crossref: 9] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
33 Weinbaum S, Cancel LM, Fu BM, Tarbell JM. The Glycocalyx and Its Role in Vascular Physiology and Vascular Related Diseases. Cardiovasc Eng Technol 2021;12:37-71. [PMID: 32959164 DOI: 10.1007/s13239-020-00485-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
34 Chinnadurai R, Scandolara R, Alese OB, Arafat D, Ravindranathan D, Farris AB, El-Rayes BF, Gibson G. Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma. Front Oncol 2020;10:1632. [PMID: 33014820 DOI: 10.3389/fonc.2020.01632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
35 Geng Z, Zhang Y, Wang S, Li H, Zhang C, Yin S, Xie C, Dai Y. Radiomics Analysis of Susceptibility Weighted Imaging for Hepatocellular Carcinoma: Exploring the Correlation between Histopathology and Radiomics Features. Magn Reson Med Sci 2021;20:253-63. [PMID: 32788505 DOI: 10.2463/mrms.mp.2020-0060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
36 Gupta M, Iyer RV. Hepatocellular Carcinoma: Special Issue Highlights. Cancers (Basel) 2020;12:E2026. [PMID: 32722037 DOI: 10.3390/cancers12082026] [Reference Citation Analysis]
37 Huang Y, Zeng J, Liu T, Xu Q, Song X, Zeng J. DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro. Cancer Manag Res 2020;12:3247-55. [PMID: 32440221 DOI: 10.2147/CMAR.S253565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
38 Allen NJ. Brain tumours manipulate neighbouring synapses. Nature 2020;578:46-7. [DOI: 10.1038/d41586-020-00137-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]